Advertisement
Table 1 Patient characteristics by anlotinib dose cohort
| Characteristic | Number of patients | |||||
|---|---|---|---|---|---|---|
| Four consecutive weeks | 2-week on/1-week off | |||||
| 5 mg/person | 10 mg/person | 10 mg/person | 12 mg/person | 16 mg/person | ||
| Total | 4 | 4 | 3 | 21 | 3 | |
| Sex | Male | 2 | 2 | 2 | 15 | 1 |
| Female | 2 | 2 | 1 | 6 | 2 | |
| Age, year | Median | 39 | 50 | 60 | 47 | 45 |
| Range | 21–49 | 39–60 | 53–65 | 32–60 | 48–55 | |
| ECOG score | 0 | 0 | 1 | 0 | 9 | 0 |
| 1 | 4 | 3 | 3 | 12 | 3 | |
| Pretreatment | Surgery | 3 | 4 | 2 | 18 | 2 |
| Radiotherapy | 2 | 1 | 3 | 6 | 1 | |
| Chemotherapy | 4 | 4 | 3 | 15 | 3 | |
| Tumor site | Sarcoma | 2 | 1 | 1 | 4 | 1 |
| MTC | 0 | 0 | 0 | 6 | 0 | |
| CC | 1 | 2 | 0 | 0 | 1 | |
| NSCLC | 0 | 0 | 1 | 3 | 0 | |
| RC | 0 | 0 | 0 | 4 | 0 | |
| Other | 1 | 1 | 1 | 4 | 1 | |
